Alogliptin benzoate

Alogliptin benzoate is an oral antihyperglycemic agent used in the treatment of type 2 diabetes. It belongs to the class of drugs known as dipeptidyl peptidase-4 inhibitors or DPP-4 inhibitors.

Pharmacology

Alogliptin benzoate works by inhibiting the enzyme dipeptidyl peptidase-4. This enzyme is involved in the breakdown of incretin hormones, which are released by the intestines in response to food intake. By inhibiting DPP-4, alogliptin benzoate increases the levels of incretin hormones in the body. These hormones help to regulate blood glucose levels by increasing insulin secretion and decreasing glucagon secretion.

Clinical Use

Alogliptin benzoate is used in the management of type 2 diabetes. It is often used in combination with other antihyperglycemic agents such as metformin or pioglitazone to achieve better glycemic control.

Side Effects

Common side effects of alogliptin benzoate include headache, nasopharyngitis, and upper respiratory tract infection. Serious side effects may include pancreatitis, hypersensitivity reactions, and hepatic dysfunction.

Contraindications

Alogliptin benzoate is contraindicated in patients with a history of hypersensitivity to alogliptin or any of the product components. It is also contraindicated in patients with a history of pancreatitis.

Drug Interactions

Alogliptin benzoate may interact with other antihyperglycemic agents, increasing the risk of hypoglycemia. It may also interact with certain antibiotics, increasing the risk of skin reactions.

See Also

• Dipeptidyl peptidase-4 inhibitors
• Type 2 diabetes
• Incretin